Ionetix Corporation

About Ionetix Corporation

Ionetix Corporation sits in Isotope Supply, a segment Bracken sees as structurally important to the radiopharma value chain.

Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.

What we're seeing

• Reuters Health · 2026-09-12
  Ionetix Corporation expands cyclotron capacity to meet Lu-177 demand
  Coverage notes the company's growing footprint in the radioligand therapy space.
• Endpoints News · 2026-06-03
  Ionetix Corporation announces Phase II readout for lead theranostic candidate
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• FierceBiotech · 2026-03-18
  Ionetix Corporation appoints new Chief Medical Officer ahead of pivotal trial
  The announcement comes amid tightening Mo-99 and Lu-177 supply.
• BioPharma Reporter · 2026-08-05
  Ionetix Corporation signs supply agreement to support late-stage trials
  The announcement comes amid tightening Mo-99 and Lu-177 supply.
• Imaging Wire · 2026-09-16
  Ionetix Corporation closes Series C round to scale radiopharma manufacturing
  The announcement comes amid tightening Mo-99 and Lu-177 supply.

Mocked while we wire the Exa integration. Headlines are illustrative.

What we expect to see at the booth

Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.